T. Rowe Price Investment Management
BIO icon

T. Rowe Price Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

T. Rowe Price Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,633
Closed -$17.8M – 678
2025
Q4 		$17.8M Sell
58,633
-6,597
-10% -$2.06M 0.01% 511
2025
Q3 		$18.3M Buy
65,230
+17,032
+35% +$4.63M 0.01% 508
2025
Q2 		$11.6M Buy
+48,198
New +$11.4M 0.01% 546

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Investment Management's BIO Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 58,633 shares — an estimated $17.8M sold.

T. Rowe Price Investment Management first reported a position in BIO in Q2 2025 and held it in 3 quarters. The position peaked at $18.3M in Q3 2025. 393 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 58,633 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $17.8M.
  • T. Rowe Price Investment Management first reported a position in Bio-Rad Laboratories Class A in Q2 2025 and held it in 3 quarters.
  • T. Rowe Price Investment Management's Bio-Rad Laboratories Class A position peaked at $18.3M in Q3 2025.
  • 393 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.